Summary of Biomarker Analysis
Method of Measurement
Biomarker Measured
Biomarker Categories
Summary completed October 2019
Biomarkers for Alzheimer’s Disease
BiomarkerAβ1-17 (Aβ17) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentPreclinical |
BiomarkerPlasma lipoproteome |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementNeuronal damage |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Biomarkerα-synuclein |
Biomarker MeasuredCSF |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerPramlintide challenge blood test (DTAD) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UseDiagnostic, Predictive |
Stage of DevelopmentClinical trials |
BiomarkerRetinal Imaging (RetAD) |
Biomarker MeasuredOptical |
Method of MeasurementVasculature |
UseDiagnostic, Monitoring |
Stage of DevelopmentClinical trials |
Biomarker4-Hydroxynonenal (HNE) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementOxidative stress |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Biomarker4-Hydroxynonenal (HNE) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementOxidative stress |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Biomarker4-Hydroxynonenal (HNE) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementOxidative stress |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Biomarker18F-AV-1451 (F 18 T807) |
Biomarker MeasuredImaging |
Method of MeasurementTau |
UsePrognostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerProteostasis-related biomarkers |
Biomarker MeasuredCSF |
Method of MeasurementAmyloid, Inflammation, Neuronal damage, Tau, Other |
UseDiagnostic, Monitoring, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerSingle Photon Emission Computed Tomography (SPECT) with DaTscan (SPECT-DaTscan) and CSF biomarkers (CLEM) |
Biomarker MeasuredImaging, CSF |
Method of MeasurementUnknown |
UsePrognostic, Predictive |
Stage of DevelopmentClinical trials |
Biomarker18F-AV-1451 (F 18 T807) |
Biomarker MeasuredImaging |
Method of MeasurementTau |
UsePrognostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerSphingolipids |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementUnknown |
UseSusceptibility/risk |
Stage of DevelopmentClinical trials |
Biomarker18F-AV-1451 (F 18 T807) |
Biomarker MeasuredImaging |
Method of MeasurementTau |
UsePrognostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerRetinal thinning |
Biomarker MeasuredOptical |
Method of MeasurementVasculature |
UseSusceptibility/risk |
Stage of DevelopmentClinical trials |
Biomarker18F-AV-1451 (F 18 T807) |
Biomarker MeasuredImaging |
Method of MeasurementTau |
UsePrognostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkersTREM2 |
Biomarker MeasuredCSF |
Method of MeasurementNeuronal damage |
UseDiagnostic, Monitoring |
Stage of DevelopmentClinical trials |
Biomarker18F-AV-1451 (F 18 T807) |
Biomarker MeasuredImaging |
Method of MeasurementTau |
UsePrognostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerSynaptic Injury and Functional Connectivity |
Biomarker MeasuredImaging, CSF |
Method of MeasurementNeuronal damage |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Biomarker[18F]MK-6240 ([18F]MNI-946) |
Biomarker MeasuredImaging |
Method of MeasurementTau |
UseMonitoring, Pharmacodynamic/response, Susceptibility/risk |
Stage of DevelopmentClinical trials |
Questions? Additional biomarkers to share? Contact Us